Artiva Biotherapeutics, Inc.

NASDAQ:ARTV

Biotechnology

Healthcare
$3.77 -3.37%

-$0.34 today

Market cap
$186.36M
Beta
2.40
P/E (TTM)
-2.7
EPS (TTM)
-$3.53
52W Low $1.47High $14.53

Volume 0.97M

Average 0.48M

ARTV Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

Artiva Biotherapeutics, Inc.NASDAQ: ARTV

Net Margin · Q1 FY2026 · quarter ended Mar 2026

Net margin not reported for Q1 FY2026

Context

  • Net margin widened in 1 of the last 2 fiscal years.
  • FY2024 was the lowest level in the 3 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
—— QoQ
Last fiscal yearDec 2025
—— YoY
LTMMar 2026
—— YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

Net Margin history

Percent of revenue · from the income statement

Latest · FY2024
-23304.0%
Year-over-year change
-23221.3pp

Net Margin vs competitors

How ARTV compares with its peers on the latest reported figures

ARTV Competitors Peer median
Net Margin for ARTV and competitors
Company Period LTM level YoY 3-year change
DTILPrecision BioSciences, Inc.LTM Mar 2026-98.7% -55.7 pp+308.8 pp
STROSutro Biopharma, Inc.LTM Mar 2026-154.2% +214.9 pp-10.6 pp
STTKShattuck Labs, Inc.LTM Mar 2026-4987.4% -3454.4 pp+10754.8 pp
CNTBConnect Biopharma Holdings LimitedFY2025-86687.5% -86627.5 pp—
IFRXInflaRx N.V.LTM Mar 2026-146303.9% -111837.5 pp—
ARTVArtiva Biotherapeutics, Inc.FY2025— ——
ZNTLZentalis Pharmaceuticals, Inc.FY2025— ——
ALXOALX Oncology Holdings Inc.FY2025— ——
GUTSFractyl Health, Inc. Common StockFY2025— ——
Peer median (excluding ARTV) -4987.4%-3454.4 pp+308.8 pp

Competitors are the stored peer set for ARTV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2M4.93M33.49M251K0
Cost of Revenue00002.6M
Gross Profit2M4.93M33.49M251K(2.6M)
Gross Margin100.0%100.0%100.0%100.0%—
Research & Development42.41M43.98M50.25M50.33M69.54M
Selling, General & Admin12.86M20.78M13.91M17.21M20.27M
Operating Expenses55.27M64.76M64.16M67.53M88.01M
Depreciation & Amortization248K1.16M2.27M2.43M2.6M
EBITDA(71.58M)(57.18M)(25.36M)(56.06M)(81.27M)
EBITDA Margin-3575.3%-1159.5%-75.7%-22335.5%—
Operating Income(53.27M)(59.83M)(30.67M)(67.28M)(90.61M)
Operating Margin-2660.9%-1213.3%-91.6%-26805.6%—
Interest Income01.29M2.54M5.35M5.96M
Interest Expense00000
Other Income / Expenses(18.55M)1.49M3.05M8.79M6.75M
Income Before Tax(71.83M)(58.34M)(27.62M)(58.49M)(83.87M)
Pre-Tax Margin-3587.7%-1183.0%-82.5%-23304.0%—
Income Tax Expense053K72K00
Net Income(71.83M)(58.39M)(27.7M)(58.49M)(83.87M)
Net Margin-3587.7%-1184.1%-82.7%-23304.0%—
EPS (Basic)(4.08)(3.32)(1.19)(5.20)(3.43)
EPS (Diluted)(4.08)(3.32)(1.19)(5.20)(3.43)
Weighted Avg Shares17.58M17.58M23.28M24.36M24.44M
Weighted Avg Shares (Diluted)17.58M17.58M23.28M24.36M24.44M

Artiva Biotherapeutics, Inc.

NASDAQ:ARTV

Intrinsic Alpha fair value

Locked

Current Price

$3.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.